The U.S. Food and Drug Administration late last year issued a warning letter to MedisourceRx, a compounding pharmacy owned by Hims & Hers, six months after a facility was cited for troubling problems during an inspection.
One violation involved a failure to report a serious adverse event experienced by a patient who had taken a compounded version of semaglutide, the chemical name for the Wegovy weight-loss medication sold by Novo Nordisk, according to an FDA inspection report of the Los Alamitos, Ca., facility last May and June.
The incident occurred in January 2025, when a patient reported “severe” stomach issues and spent three nights in a hospital after taking the compounded injectable drug. But MedisourceRx, which Hims & Hers had acquired in September 2024did not report the problem to the FDA within 15 days after receiving the information as required by law.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in